Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-28T02:34:40.621Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparative Trial of Ro 4-6270 and Amitriptyline in Depressive Illness

Published online by Cambridge University Press:  29 January 2018

Ijaz Haider
Ijaz Haider*
Affiliation:
Department of Child and Family Psychiatry, Playfield House, Cupar, Fife; St. Francis and Hurstwood Park Hospitals, Haywards Heath, Sussex
Get access Rights & Permissions [Opens in a new window]

Extract

Many patients with depressive illness also show considerable anxiety and agitation and often require a tranquillizer in addition to an anti-depressant drug. A new combination—Ro 4-6270 or Limbitrol Forte (Roche)—consisting of amitriptyline 25 mg.+chlordiazepoxide 10 mg. has recently become available for clinical trial. Both amitriptyline and chlordiazepoxide are widely used as an anti-depressant and a tranquillizer respectively. Clinical trials by Harris (1960), Jenner et al. (1961) and Hordern et al. (1963) have confirmed the efficacy of these drugs. Karabanow (1962), Poldinger (1963), Tietzen (1964) and Haider (1967a) have reported the usefulness of the combination of amitriptyline and chlordiazepoxide in depressive states, but none of these studies was adequately controlled. In a previous study (Haider, 1967b) I reported the efficacy of a combination of an anti-depressant and a tranquillizer in improving anxiety and agitation in depressive illness, more than one would expect with an anti-depressant alone. As the combination was compared with a placebo, it was not possible to state with any certainty what was the role of the tranquillizer in improving these symptoms.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 502 , September 1967 , pp. 993 - 998
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Browne, M. W., Kreeger, L. C., and Kazamias, N. G. (1963). “A clinical trial of amitriptyline in depressive patients.” Brit. J. Psychiat., 109, 692–694.Google Scholar
Haider, , Ijaz, (1967a). “Combination of amitriptyline and chlordiazepoxide in depressive states.” Brit. J. clinical Practice, 21, 39–40.Google Scholar
Haider, , Ijaz, (1967b). “Amitriptyline and perphenazine in depressive illness: a controlled trial.” Brit. J. Psychiat., 113, 195–199.Google Scholar
Harris, T. D. (1960). “Methamine diazepoxide.” J. Amer. med. Ass., 172, 1163–1164.CrossRefGoogle Scholar
Hordern, A., Holt, N. E., Burt, C. G., and Gordon, W. F. (1963). “Amitriptyline in depressive states. Phenomenology and prognostic considerations.” Brit. J. Psychiat., 109, 815–825.Google Scholar
Jenner, F. A., Kerry, R. J., and Parkin, D. (1961). “A controlled trial of methamine diazepoxide (‘Librium’) Roche in the treatment of anxiety in neurotic patients.” J. ment. Sci., 107, 575–582.Google Scholar
Karabanow, O. (1962). “Amitriptyline in depressive states.” Appl. Therap., 4, 638–641.Google Scholar
Medical Research Council (1965). “Clinical trial of the treatment of depressive illness.” Report by the Clinical Psychiatry Committee. Brit. med. J., i, 881–886.Google Scholar
Poldinger, W. (1963). “Laroxyl (amitriptylin): ein Thymolepticum mit neuroleptischer Wirkungskomponente.” [“Laroxyl (amitriptyline): a thymoleptic agent with neuroleptic activity.”] Nervenartz, 34, 80–84.Google Scholar
Tietzen, A. (1964). “Zur kombinierten medikamentosen Behandlung depressiver Zustandsbilder in der freien Praxis.” [“Combined drug treatment of depressive syndromes in general practice.”] Med. Klin., 59, 1758–1761.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.